Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 2
2018 2
2019 1
2020 6
2021 7
2022 5
2023 3
2024 1
2025 7
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque LI, Lloyd A, Ahmad N, Liu Y, Tiv S, Millard T, Gagliardi L, Kolanu N, Barmanray RD, McMorrow R, Raygoza Cortez AK, White H, Chen X, Zhou X, Liu J, Rodríguez AF, González-Colmenero AD, Wang Y, Li L, Sutanto S, Solis RC, Díaz González-Colmenero F, Rodriguez-Gutierrez R, Walsh M, Guyatt G, Strippoli GFM. Palmer SC, et al. Among authors: mustafa ra. BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573. BMJ. 2021. PMID: 33441402 Free PMC article.
Results included estimated absolute effects of treatment per 1000 patients treated for five years for patients at very low risk (no cardiovascular risk factors), low risk (three or more cardiovascular risk factors), moderate risk (cardiovascular disease), hig …
Results included estimated absolute effects of treatment per 1000 patients treated for five years for patients at very low risk (no cardi …
Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Rydén L, Marx N, Brosius FC 3rd, Mustafa RA, Agarwal A, Zou X, Mao Y, Asadollahifar A, Chowdhury SR, Zhai C, Gupta S, Gao Y, Lima JP, Numata K, Qiao Z, Fan Q, Yang Q, Jin Y, Ge L, Yang Q, Zhu H, Yang F, Chen Z, Lu X, He S, Chen X, Lyu X, An X, Chen Y, Hao Q, Standl E, Siemieniuk R, Agoritsas T, Tian H, Li S. Shi Q, et al. Among authors: mustafa ra. BMJ. 2023 Apr 6;381:e074068. doi: 10.1136/bmj-2022-074068. BMJ. 2023. PMID: 37024129 Free PMC article.
The study confirmed the benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular death, non-fatal myocardial infarction, admission to hospital for heart failure, and end stage kidney disease. ...Absolute benefits of SGLT-2 inhibitors, GLP-1 rece …
The study confirmed the benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular death, non-fatal myocard …
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary.
Torres VE, Ahn C, Barten TRM, Brosnahan G, Cadnapaphornchai MA, Chapman AB, Cornec-Le Gall E, Drenth JPH, Gansevoort RT, Harris PC, Harris T, Horie S, Liebau MC, Liew M, Mallett AJ, Mei C, Mekahli D, Odland D, Ong ACM, Onuchic LF, Pei YP, Perrone RD, Rangan GK, Rayner B, Torra R, Balk EM, Gordon CE, Earley A, Mustafa RA, Devuyst O. Torres VE, et al. Among authors: mustafa ra. Kidney Int. 2025 Feb;107(2):234-254. doi: 10.1016/j.kint.2024.07.010. Kidney Int. 2025. PMID: 39848746 Free article.
American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.
Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, Linkins LA, Rodner SB, Selleng S, Warkentin TE, Wex A, Mustafa RA, Morgan RL, Santesso N. Cuker A, et al. Among authors: mustafa ra. Blood Adv. 2018 Nov 27;2(22):3360-3392. doi: 10.1182/bloodadvances.2018024489. Blood Adv. 2018. PMID: 30482768 Free PMC article.
The recommendations address screening of asymptomatic patients for HIT, diagnosis and initial management of patients with suspected HIT, treatment of acute HIT, and special situations in patients with acute HIT or a history of HIT, including cardiovascular surgery, percuta …
The recommendations address screening of asymptomatic patients for HIT, diagnosis and initial management of patients with suspected HIT, tre …
Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary.
Al-Makki A, DiPette D, Whelton PK, Murad MH, Mustafa RA, Acharya S, Beheiry HM, Champagne B, Connell K, Cooney MT, Ezeigwe N, Gaziano TA, Gidio A, Lopez-Jaramillo P, Khan UI, Kumarapeli V, Moran AE, Silwimba MM, Rayner B, Sukonthasan A, Yu J, Saraffzadegan N, Reddy KS, Khan T. Al-Makki A, et al. Among authors: mustafa ra. Hypertension. 2022 Jan;79(1):293-301. doi: 10.1161/HYPERTENSIONAHA.121.18192. Epub 2021 Nov 15. Hypertension. 2022. PMID: 34775787 Free PMC article.
Hypertension is a major cause of cardiovascular disease and deaths worldwide especially in low- and middle-income countries. ...
Hypertension is a major cause of cardiovascular disease and deaths worldwide especially in low- and middle-income countries. ...
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.
Li S, Vandvik PO, Lytvyn L, Guyatt GH, Palmer SC, Rodriguez-Gutierrez R, Foroutan F, Agoritsas T, Siemieniuk RAC, Walsh M, Frere L, Tunnicliffe DJ, Nagler EV, Manja V, Åsvold BO, Jha V, Vermandere M, Gariani K, Zhao Q, Ren Y, Cartwright EJ, Gee P, Wickes A, Ferns L, Wright R, Li L, Hao Q, Mustafa RA. Li S, et al. Among authors: mustafa ra. BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091. BMJ. 2021. PMID: 33975892
This has changed through trials demonstrating atherosclerotic cardiovascular disease (CVD) and chronic kidney disease (CKD) benefits independent of medications' glucose-lowering potential. ...More than three cardiovascular risk factors without established CVD or CKD …
This has changed through trials demonstrating atherosclerotic cardiovascular disease (CVD) and chronic kidney disease (CKD) benefits …
Evaluation and management of obstructive sleep apnea in adults hospitalized for medical care: an American Academy of Sleep Medicine clinical practice guideline.
Mehra R, Auckley DH, Johnson KG, Billings ME, Carandang G, Falck-Ytter Y, Khayat RN, Mustafa RA, Pena-Orbea C, Sahni AS, Sharma S, Patil SP. Mehra R, et al. Among authors: mustafa ra. J Clin Sleep Med. 2025 Dec 1;21(12):2193-2203. doi: 10.5664/jcsm.11864. J Clin Sleep Med. 2025. PMID: 40838698
When considering in-hospital screening as part of a management pathway, (1) patients who place a lower value on the potential reduction of clinically meaningful outcomes (eg, cardiovascular events) and place a higher value on the possible downsides associated with the use …
When considering in-hospital screening as part of a management pathway, (1) patients who place a lower value on the potential reduction of c …
American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism.
Monagle P, Cuello CA, Augustine C, Bonduel M, Brandão LR, Capman T, Chan AKC, Hanson S, Male C, Meerpohl J, Newall F, O'Brien SH, Raffini L, van Ommen H, Wiernikowski J, Williams S, Bhatt M, Riva JJ, Roldan Y, Schwab N, Mustafa RA, Vesely SK. Monagle P, et al. Among authors: mustafa ra. Blood Adv. 2018 Nov 27;2(22):3292-3316. doi: 10.1182/bloodadvances.2018024786. Blood Adv. 2018. PMID: 30482766 Free PMC article.
Prognostic models for cardiovascular and kidney outcomes in people with type 2 diabetes: living systematic review and meta-analysis of observational studies.
Rayner DG, Shah D, Dai SC, Gou D, Chen JZX, Agarwal A, Mustafa RA, Manja V, Olav Vandvik P, Agoritsas T, Foroutan F. Rayner DG, et al. Among authors: mustafa ra. BMJ Med. 2025 Aug 14;4(1):e001369. doi: 10.1136/bmjmed-2025-001369. eCollection 2025. BMJ Med. 2025. PMID: 40832127 Free PMC article.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Studies validating prognostic models that predicted all cause and cardiovascular mortality, admission to hospital for heart failure, kidney failure, myocardial infarction, or ischaemic stroke in adults with type 2 diabetes mellit …
ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Studies validating prognostic models that predicted all cause and cardiovascular mortalit …
Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses.
Buchan TA, Malik A, Chan C, Chambers J, Suk Y, Zhu JW, Ge FZ, Huang LM, Vargas LA, Hao Q, Li S, Mustafa RA, Vandvik PO, Guyatt G, Foroutan F. Buchan TA, et al. Among authors: mustafa ra. Heart. 2021 Dec;107(24):1962-1973. doi: 10.1136/heartjnl-2021-319243. Epub 2021 Apr 8. Heart. 2021. PMID: 33833070
OBJECTIVE: To inform a clinical practice guideline (BMJ Rapid Recommendations) considering sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists for treatment of adults with type 2 diabetes, we summarised the available evidence regarding the perf …
OBJECTIVE: To inform a clinical practice guideline (BMJ Rapid Recommendations) considering sodium glucose cotransporter-2 inhibitors and glu …
33 results